(
out of
115
reviews
)
Clinical Locations
Primary Location
Huntsman Cancer Institute - Cancer Hospital South
Clinic 2B, Urology
1950 Circle of Hope
Salt Lake City
,
UT
84112
Specialties
Board Certification
|
American Board of Internal Medicine (Sub: Medical Oncology)
|
Patient Rating
Patients consistently describe Dr. Gupta as knowledgeable, thorough, and professional, with clear explanations of diagnoses and treatment options. Many highlight her compassionate, patient-centered approach—she listens, answers questions, and spends time ensuring people understand their care. Her clinical team is also praised as responsive and supportive, helping patients feel confident and reassured about their treatment.
Generated via Patient Reviews
4.9
/5
( out of
115 reviews
)
The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers. The scale on which responses are measured is 1 to 5 with 5 being the best score.
Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.
Board Certification and Academic Information
| Academic Departments |
Internal Medicine
-Associate Professor |
|---|---|
| Academic Divisions |
Oncology
|
| Board Certification |
American Board of Internal Medicine (Sub: Medical Oncology)
|
Education history
| Undergraduate | High School - Atomic Energy Junior College | Higher Secondary Certificate |
|---|---|---|
| Professional Medical | Medical School - King Edward Memorial hospital and Seth G.S Medical College, Mumbai, India | MD |
| Residency | Internal Medicine - Nassau University Medical Center | Resident |
| Fellowship | Geriatric Medicine - Baylor College of Medicine | Fellow |
| Fellowship | Medical Oncology - University of Utah, Huntsman Cancer Institute | Fellow |
Selected Publications
Journal Article
- Obermayer A, Davis J, Talada DP, Teng M, Eschrich S, Yin V, Spakowicz D, Chatterjee D, Rounbehler RJ, Churchman ML, Tarhini AA, Wang X, Gupta S, Markowitz J, Goecks J, Li R, Rodrigues Pessoa R, Manley BJ, Tan AC, Grass GD, Chen DT, Shaw T (2026). ShinyEvents: harmonizing longitudinal data for real-world survival estimation. NPJ precision oncology, 10(1), 54.
- Gebrael G, Jo Y, Ozay ZI, Nandakumar V, Cigliola A, Tateo V, Lin E, Ostrowski M, Sayegh N, Murdock E, Mathew Thomas V, Gupta S, Agarwal N, Swami (2026). Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab. Bladder cancer (Amsterdam, Netherlands), 12(1), 23523735261437911.
- van Onselen J, Winn M, Gomez-Lumbreras A, Dunlap CE, Bhatia R, Gupta S, Cohan JN, Hardikar (2026). Allostatic load, multimorbidity, and overall and cancer-specific survival among older adults in the United States. Cancer epidemiology, biomarkers & prevention,
- Hoobler R, Maschek JA, Luo B, Murphy EA, Kubinak JL, Stewart PA, Cox JE, Chaix A, Woodruff K, Sanchez A, Coletta AM, Tabung FK, Gupta S, Hardikar S, Colman H, Playdon M (2026). Identification of circulating lipidomic biomarkers of malnutrition risk among oncology patients in the Total Cancer Care (TCC) Study: a cross-sectional analysis. The Journal of nutrition, 101603.
- Adler ER, Mohammad A, Kumar P, Rounbehler RJ, Churchman ML, Graham LS, Singer EA, Salhia B, Ayanambakkam A, Nepple KG, Myint ZW, Li Q, Ghodoussipour S, King JM, Grass GD, Gupta SV, Viscuse P (2026). Insulin Pathway Changes in Localized Prostate Cancer: A Multi-Institutional Analysis. Cancers, 18(10),
- Adler ER, Mohammad A, Kumar P, Rounbehler RJ, Churchman ML, Graham LS, Singer EA, Salhia B, Ayanambakkam A, Nepple KG, Myint ZW, Li Q, Ghodoussipour S, King JM, Grass GD, Gupta SV, Viscuse P (2026). Insulin Pathway Changes in Localized Prostate Cancer: A Multi-Institutional Analysis. Cancers, 18(10),
- Jain RK, Swami U, Bilen MA, Gebrael G, Boucher KM, Braun E, Brown JT, Chahoud J, Gupta S, Agarwal N, Sonpavde G, Maughan B (2025). Cabozantinib plus Pembrolizumab as First-line Therapy for Cisplatin-ineligible Advanced Urothelial Carcinoma: The PemCab Trial. European urology oncology, 8(4), 952-960.
- Lee H, Shen J, Fadlullah MZ, Neibling A, Hanson C, Ampaw E, Lin T, Larsen M, Lloyd J, Maughan BL, Swami U, Gupta S, Tward J, Johnson SB, O'Neil B, Schmidt B, Dechet CB, Haaland B, Wang L, Tan AC, Kohli (2025). Circulatory prostate cancer proteome landscapes and prognostic biomarkers in metastatic castrate resistant prostate cancer. Clinical proteomics, 22(1), 13.
- Galarza Fortuna GM, Grass D, Maughan BL, Jain RK, Dechet C, Beck J, Schuetz E, Sanchez A, O'Neil B, Poch M, Li R, Lloyd S, Tward J, Phunrab T, Hawks JL, Swami U, Boucher KM, Agarwal N, Gupta (2025). Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT). Journal for immunotherapy of cancer, 13(3),
- Tward J, Lloyd S, Johnson S, Dechet C, Nei BO, Maughan B, Swami U, Gupta S, Sanchez A, Kokeny K, Agarwal (2025). A Phase 2 Trial of Radium(223) and Stereotactic Ablative Radiation Therapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR Study. International journal of radiation oncology, biology, physics,
- Masur J, Ratan A, Wierbilowicz K, Ayanambakkam A, Churchman ML, Graham LS, Grass GD, Gupta S, Kern SQ, King J, Myint Z, Rounbehler RJ, Salhia B, Singer EA, Zakharia Y, Paschal BM, Viscuse P (2025). Clinical and Genomic Features of Androgen Indifferent Prostate Cancer. International journal of molecular sciences, 26(2),
- Sayegh N, Jo Y, Gebrael G, Tripathi N, Chigarira B, Srivastava A, Nordblad B, Dal E, Hage Chehade C, Mahlow J, Maughan BL, Gupta S, Agarwal N, Swami (2025). Real-world Effectiveness of Single-Agent Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma. Clinical genitourinary cancer, 23(1), 102287.
- Ostrowski M, Jo Y, Hage Chehade C, Ozay ZI, Gebrael G, Sayegh N, Lin E, Srivastava A, Gordhamer A, Ji R, Li H, Mathew Thomas V, Gupta S, Riaz IB, Maughan BL, Roy S, Agarwal N, Swami (2025). Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations. JAMA network open, 8(10), e2534968.
- Feng BJ, Kohlmann W, Nix DA, Atkinson A, Boucher KM, Carroll C, Stubben CJ, Kolesar J, Singer EA, Riedlinger G, Edge S, Sahu KK, Churchman M, Graham L, Salhia B, Sanchez A, Zakharia Y, Schneider BP, Jain R, Byrne L, Moskaluk CA, Nepple K, Shabsigh A, Chahoud J, Cairns BR, Gupta (2025). Germline whole-exome sequencing reveals FOXP3-related gene variants conferring urinary cancer susceptibility and associated with immune escape. Journal for immunotherapy of cancer, 13(9),
- Grivas P, Pouessel D, Park CH, Barthelemy P, Bupathi M, Petrylak DP, Agarwal N, Gupta S, Fléchon A, Ramamurthy C, Davis NB, Recio-Boiles A, Sternberg CN, Bhatia A, Pichardo C, Sierecki M, Tonelli J, Zhou H, Tagawa ST, Loriot (2024). Sacituzumab Govitecan in Combination With Pembrolizumab for Patients With Metastatic Urothelial Cancer That Progressed After Platinum-Based Chemotherapy: TROPHY-U-01 Cohort 3. Journal of clinical oncology, JCO2202835.
- Loriot Y, Petrylak DP, Rezazadeh Kalebasty A, Fléchon A, Jain RK, Gupta S, Bupathi M, Beuzeboc P, Palmbos P, Balar AV, Kyriakopoulos CE, Pouessel D, Sternberg CN, Tonelli J, Sierecki M, Zhou H, Grivas P, Barthélémy P, Tagawa S (2024). TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes. Annals of oncology,
- Necchi A, Pouessel D, Leibowitz R, Gupta S, Fléchon A, García-Donas J, Bilen MA, Debruyne PR, Milowsky MI, Friedlander T, Maio M, Gilmartin A, Li X, Veronese ML, Loriot (2024). Pemigatinib for metastatic or surgically unresectable urothelial carcinoma with FGF/FGFR genomic alterations: final results from FIGHT-201. Annals of oncology, 35(2), 200-210.
- Sahu KK, Li H, Mathew Thomas V, Benson M, Boucher K, Gupta S, Kohli M, Swami U, Agarwal N, Maughan B (2024). A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating "BRCAness" Genotype (ROAR). The oncologist, 29(5), 450-e725.
- Tripathi N, Gebrael G, Chigarira B, Sahu KK, Balasubramanian I, Caparas C, Mathew Thomas V, Cohan JN, Pelletier K, Maughan BL, Agarwal N, Swami U, Gupta (2024). Treatment Patterns and Outcomes by Age in Metastatic Urinary Tract Cancer: A Retrospective Tertiary Cancer Center Analysis. Cancers, 16(11),
- Kohlmann W, Nix DA, Pauley K, Greenberg S, Atkinson A, Boucher KM, Kolesar J, Singer EA, Edge SB, Churchman ML, Graham L, Salhia B, Sanchez A, Zakharia Y, Nepple KG, Schneider BP, Byrne L, Jain RK, Chahoud J, Feng BJ, Gupta (2024). Inherited Germline Variants in Urinary Tract Cancer: A Multicenter Whole-Exome Sequencing Analysis and Correlation With Clinical Features and Tumor Genomics. JCO precision oncology, 8, e2300697.
- Mathew Thomas V, Jo Y, Tripathi N, Roy S, Chigarira B, Narang A, Gebrael G, Hage Chehade C, Sayegh N, Galarza Fortuna G, Ji R, Campbell P, Li H, Agarwal N, Gupta S, Swami (2024). Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US. JAMA network open, 7(5), e249417.
- Coletta AM, Simon LH, Maslana K, Taylor S, Larson K, Hansen PA, Thomas VM, Ulrich CM, Kohli M, Chipman J, Swami U, Gupta S, Maughan BL, Agarwal (2024). Creatine supplementation and resistance training to preserve muscle mass and attenuate cancer progression (CREATINE-52): a protocol for a double-blind randomized controlled trial. BMC cancer, 24(1), 493.
- Swami U, Hong A, Diessner B, Young C, Bunner SH, Xie B, Ramaswamy K, Chastek B, Chaar NE, Gupta (2024). Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States. Future oncology (London, England), 20(32), 1-14.
- Swami U, Hong A, Diessner B, Young C, Bunner SH, Xie B, Ramaswamy K, Chastek B, El Chaar N, Gupta (2024). Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States. Future oncology (London, England), 20(32), 2467-2480.
- Hage Chehade C, Jo Y, Gebrael G, Tripathi N, Sayegh N, Chigarira B, Mathew Thomas V, Galarza Fortuna G, Narang A, Campbell P, Gupta S, Maughan BL, Roy S, Agarwal N, Swami (2024). Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers. JAMA network open, 7(7), e2423186.
- Rudin CM, Pandha HS, Zibelman M, Akerley WL, Harrington KJ, Day D, Hill AG, O'Day SJ, Clay TD, Wright GM, Jennens RR, Gerber DE, Rosenberg JE, Ralph C, Campbell DC, Curti BD, Merchan JR, Ren Y, Schmidt EV, Guttman L, Gupta (2023). Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors. Journal for immunotherapy of cancer, 11(1),
- Leidner R, Conlon K, McNeel DG, Wang-Gillam A, Gupta S, Wesolowski R, Chaudhari M, Hassounah N, Lee JB, Ho Lee L, O'Keeffe JA, Lewis N, Pavlakis GN, Thompson J (2023). First-in-human phase I/Ib study of NIZ985, a recombinant heterodimer of IL-15 and IL-15R¿, as a single agent and in combination with spartalizumab in patients with advanced and metastatic solid tumors. Journal for immunotherapy of cancer, 11(10),
- Li H, Sahu KK, Kumar SA, Tripathi N, Sayegh N, Nordblad B, Chigarira B, Gupta S, Maughan BL, Agarwal N, Swami (2023). Access to Care and Healthcare Quality Metrics for Patients with Advanced Genitourinary Cancers in Urban versus Rural Areas. Cancers, 15(21),
- Li H, Sahu KK, Brundage J, Benson M, Swami U, Boucher KM, Gupta S, Hawks J, Sirohi D, Agarwal N, Maughan B (2023). Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma. The oncologist, 28(8), 737-e693.
- Doroshow DB, O'Donnell PH, Hoffman-Censits JH, Gupta SV, Vaishampayan U, Heath EI, Garcia P, Zhao Q, Yu M, Milowsky MI, Galsky M (2023). Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations. JCO precision oncology, 7, e2300095.
- Gumbleton M, Allan S, Conway H, Boucher K, Marvin J, Hawks J, Burnett W, Van Brocklin M, Whisenant J, Gilcrease G, Gupta (2023). A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE). BMC research notes, 16(1), 16.
- Li H, Sahu KK, Kumar SA, Nordblad B, Sayegh N, Tripathi N, Thomas VM, Gupta S, Maughan BL, Agarwal N, Swami (2022). A retrospective study to evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with advanced genitourinary cancers. Heliyon, 8(9), e10583.
- Tripathi N, Jo Y, Tripathi A, Sayegh N, Li H, Nussenzveig R, Haaland B, Thomas VM, Gupta S, Maughan BL, Swami U, Pal SK, Grivas P, Agarwal N, Sirohi (2022). Genomic landscape of locally advanced or metastatic urothelial carcinoma with squamous differentiation compared to pure urothelial carcinoma. Urologic oncology, 40(11), 493.e1-493.e7.
- Larkin J, Oya M, Martignoni M, Thistlethwaite F, Nathan P, Ornstein MC, Powles T, Beckermann KE, Balar AV, McDermott D, Gupta S, Philips GK, Gordon MS, Uemura H, Tomita Y, Wang J, Michelon E, di Pietro A, Choueiri T (2022). Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial. The oncologist,
- Sahu KK, Johnson ED, Butler K, Li H, Boucher KM, Gupta (2022). Improving Bone Health in Patients with Metastatic Prostate Cancer with the Use of Algorithm-Based Clinical Practice Tool. Geriatrics (Basel, Switzerland), 7(6),
- Grivas P, Loriot Y, Morales-Barrera R, Teo MY, Zakharia Y, Feyerabend S, Vogelzang NJ, Grande E, Adra N, Alva A, Necchi A, Rodriguez-Vida A, Gupta S, Josephs DH, Srinivas S, Wride K, Thomas D, Simmons A, Loehr A, Dusek RL, Nepert D, Chowdhury (2021). Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS). BMC cancer, 21(1), 593.
- Dotan E, Walter LC, Browner IS, Clifton K, Cohen HJ, Extermann M, Gross C, Gupta S, Hollis G, Hubbard J, Jagsi R, Keating NL, Kessler E, Koll T, Korc-Grodzicki B, McKoy JM, Misra S, Moon D, O'Connor T, Owusu C, Rosko A, Russell M, Sedrak M, Siddiqui F, Stella A, Stirewalt DL, Subbiah IM, Tew WP, Williams GR, Hollinger L, George GV, Sundar (2021). NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021. Journal of the National Comprehensive Cancer Network, 19(9), 1006-1019.
- Ravi P, Pond GR, Diamantopoulos LN, Su C, Alva A, Jain RK, Skelton WP 4th, Gupta S, Tward JD, Olson KM, Singh P, Grunewald CM, Niegisch G, Lee JL, Gallina A, Bandini M, Necchi A, Mossanen M, McGregor BA, Curran C, Grivas P, Sonpavde G (2021). Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration. BJU international, 128(5), 607-614.
- Lyou Y, Rosenberg JE, Hoffman-Censits J, Quinn DI, Petrylak D, Galsky M, Vaishampayan U, De Giorgi U, Gupta S, Burris H, Rearden J, Li A, Xu C, Andresen C, Moran S, Daneshmand S, Bajorin D, Pal SK, Grivas (2021). Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma. Clinical genitourinary cancer,
- Conlon K, Watson DC, Waldmann TA, Valentin A, Bergamaschi C, Felber BK, Peer CJ, Figg WD, Potter EL, Roederer M, McNeel DG, Thompson JA, Gupta S, Leidner R, Wang-Gillam A, Parikh NS, Long D, Kurtulus S, Ho Lee L, Chowdhury NR, Bender F, Pavlakis G (2021). Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors. Journal for immunotherapy of cancer, 9(11),
- Bleicher J, McGuire LE, Robbins RB, Johnson JE, Fischbuch S, Gupta S, Beck AC, Cohan J (2021). Preoperative Advance Care Planning for Older Adults Undergoing Major Abdominal Surgery. The American journal of hospice & palliative care, 39(4), 10499091211020276.
- Grivas P, Kiedrowski LA, Sonpavde GP, Gupta SV, Thomas RA, Gourdin TS, Hardin AI, Hamann KM, Faltas BM, Vogelzang N (2021). Spectrum of FGFR2/3 Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma. Bladder cancer (Amsterdam, Netherlands), 7(2), 143-148.
- Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R, MK-6482-004 Investigator (2021). Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. The New England journal of medicine, 385(22), 2036-2046.
- Hanson HA, Leiser CL, O'Neil B, Martin C, Gupta S, Smith KR, Dechet C, Lowrance WT, Madsen MJ, Camp N (2020). Harnessing Population Pedigree Data and Machine Learning Methods to Identify Patterns of Familial Bladder Cancer Risk. Cancer epidemiology, biomarkers & prevention, 29(5), 918-926.
- Pal SK, Bajorin D, Dizman N, Hoffman-Censits J, Quinn DI, Petrylak DP, Galsky MD, Vaishampayan U, De Giorgi U, Gupta S, Burris HA, Soifer HS, Li G, Wang H, Dambkowski CL, Moran S, Daneshmand S, Rosenberg J (2020). Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. Cancer, 126(11), 2597-2606.
- Galsky MD, Mortazavi A, Milowsky MI, George S, Gupta S, Fleming MT, Dang LH, Geynisman DM, Walling R, Alter RS, Kassar M, Wang J, GS, Davis N, Picus J, Philips G, Quinn DI, Haines GK 3rd, Hahn NM, Zhao Q, Yu M, Pal S (2020). Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. Journal of clinical oncology, 38(16), 1797-1806.
- Neeraj Agarwal, Roberto Nussenzveig, Andrew W Hahn, John M Hoffman, Kathryn Morton, Sumati Gupta, Julia Batten, Jared Thorley, Josiah Hawks, Victor Sacristan Santos, Gayatri Nachaegari, Xuechen Wang, Kenneth Boucher, Benjamin Haaland, Benjamin L Maugha (2020). Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer PMID: 31937614 DOI:10.1158/1078-0402 CCR-19 -2591 . Clinical cancer research, 26(9), 2104-2110.
- Russell W Madison, Sumati V Gupta, Yasir Y Elamin, Douglas I Lin, Sumanta K Pal, Andrea Necchi, Vincent A Miller, Jeffrey S Ross, Jon H Chung, Brian M Alexander, Alexa B Schrock, John V Heymach, Prasanth Reddy, Siraj Al (2020). Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions PMID: 31985116 DOI: 10.1111/bju.15006. BJU international, 125(5), 739-746.
- Hu-Lieskovan S, Bhaumik S, Dhodapkar K, Grivel JJB, Gupta S, Hanks BA, Janetzki S, Kleen TO, Koguchi Y, Lund AW, Maccalli C, Mahnke YD, Novosiadly RD, Selvan SR, Sims T, Zhao Y, Maecker H (2020). SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery. Journal for immunotherapy of cancer, 8(2),
- Grivas P, Lalani AA, Pond GR, Nagy RJ, Faltas B, Agarwal N, Gupta SV, Drakaki A, Vaishampayan UN, Wang J, Barata PC, Gopalakrishnan D, Naik G, McGregor BA, Kiedrowski LA, Lanman RB, Sonpavde G (2020). Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. European urology oncology, 3(5), 695-699.
- Lyou Y, Grivas P, Rosenberg JE, Hoffman-Censits J, Quinn DI, P Petrylak D, Galsky M, Vaishampayan U, De Giorgi U, Gupta S, Burris H, Rearden J, Li A, Wang H, Reyes M, Moran S, Daneshmand S, Bajorin D, Pal S (2020). Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma. European urology, 78(6), 916-924.
- Halwani AS, Rasmussen KM, Patil V, Li CC, Yong CM, Burningham Z, Gupta S, Narayanan S, Lin SW, Carroll S, Mhatre SK, Graff JN, Dreicer R, Sauer B (2020). Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer. Urologic oncology, 38(1), 1.e1-1.e10.
- Grivas P, Mortazavi A, Picus J, Hahn NM, Milowsky MI, Hart LL, Alva A, Bellmunt J, Pal SK, Bambury RM, O'Donnell PH, Gupta S, Guancial EA, Sonpavde GP, Faltaos D, Potvin D, Christensen JG, Chao RC, Rosenberg J (2019). Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer, 125(4), 533-540.
- Gupta S, Albertson DJ, Parnell TJ, Butterfield A, Weston A, Pappas LM, Dalley B, O'Shea JM, Lowrance WT, Cairns BR, Schiffman JD, Sharma (2019). Histone deacetylase inhibition has targeted clinical benefit in ARID1A mutated advanced urothelial carcinoma.Epub 2018 Oct 9PMID: 30301863 DOI: 10.1158/1535-7163.MCT-17-0957. Molecular cancer therapeutics, 18(1), 185-195.
- Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata PC, Drakaki A, Faltas BM, Kiedrowski LA, Lanman RB, Nagy RJ, Vogelzang NJ, Boucher KM, Vaishampayan UN, Sonpavde G, Grivas (2018). Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer, 124(10), 2115-2124.
- Martin C, Leiser CL, O'Neil B, Gupta S, Lowrance WT, Kohlmann W, Greenberg S, Pathak P, Smith KR, Hanson H (2018). Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. Journal of the National Cancer Institute, 110(5), 527-533.
- Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini B (2018). Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.LID - S1470-2045(18)30107-4 [pii]LID - 10.1016/S1470-2045(18)30107-4 [doi]. The Lancet. Oncology, 19, 451-460.
- Gupta S, Albertson D, Gaston D, Heilbrun ME, Agarwal N, Boucher K, Parnell TJ, Liu T, Morgans A, Madison R, Gowen K, Miller VA, Ross JS, Ali SM, Millis S (2018). Comprehensive Genomic Sequencing of Urothelial Tumors Identifies Rare SMARCB1 (INI-1)-Deficient Carcinomas of the Urinary System. Clinical genitourinary cancer, 16(2), e373-e382.
- Gupta S, Doyle K, Mosbruger TL, Butterfield A, Weston A, Ast A, Kaadige M, Verma A, Sharma (2018). Reversible LSD1 inhibition with HCI-2509 induces the p53 gene expression signature and disrupts the MYCN signature in high-risk neuroblastoma cells. Oncotarget, 9(11), 9907-9924.
- Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grünwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Sharma S, Mortazavi A, Vaughn DJ, Isaacs R, Parker K, Chen X, Yu K, Porter D, Graus Porta D, Bajorin D (2018). Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations. Cancer discovery, 8(7), 812-821.
- Gupta S, Greenberg S, Grimmett J, Gaston D, Agarwal N, Lowrance W, Schiffman J, Kohlmann (2017). Inherited DNA repair gene mutations detected by tumor next generation sequencing in urinary tract cancers. Familial cancer, 16(4), 545-550.
- Gill D, Gaston D, Bailey E, Hahn A, Gupta S, Batten J, Alex A, Boucher K, Stenehjem D, Agarwal (2017). Efficacy of Eplerenone in the Management of Mineralocorticoid Excess in Men With Metastatic Castration-resistant Prostate Cancer Treated With Abiraterone Without Prednisone. Clinical genitourinary cancer, 15(4), e599-e602.
- Hahn AW, Gill DM, Maughan B, Agarwal A, Arjyal L, Gupta S, Streeter J, Bailey E, Pal SK, Agarwal (2017). Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. Oncotarget, 8(20), 33614-33620.
- Agarwal N, McPherson JP, Bailey H, Gupta S, Werner TL, Reddy G, Bhat G, Bailey EB, Sharma (2016). A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. Cancer chemotherapy and pharmacology, 77(2), 299-308.
- Bailey H, McPherson JP, Bailey EB, Werner TL, Gupta S, Batten J, Reddy G, Bhat G, Sharma S, Agarwal (2016). A phase I study to determine the pharmacokinetics and urinary excretion of belinostat and metabolites in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 78(5), 1059-1071.
- Gupta S, Gouw L, Wright J, Chawla S, Pitt D, Wade M, Boucher K, Sharma (2016). Phase II study of amrubicin (SM-5887), a synthetic 9-aminoanthracycline, as first line treatment in patients with metastatic or unresectable soft tissue sarcoma: durable response in myxoid liposarcoma with TLS-CHOP translocation. Investigational new drugs, 34(2), 243-52.
- Gupta S, Weston A, Bearrs J, Thode T, Neiss A, Soldi R, Sharma (2016). Reversible Lysine-Specific Demethylase 1 antagonist HCI-2509 inhibits growth and decreases c-myc in castration-resistant and docetaxel-resistant prostate cancer cells. Prostate cancer and prostatic diseases,
- Gill DM, Stenehjem DD, Parikh K, Merriman J, Sendilnathan A, Agarwal AM, Hahn AW, Gupta S, Tantravahi SK, Samlowski WE, Agarwal (2016). Conditional survival of metastatic renal cell carcinoma patients treated with high-dose interleukin-2. Ecancermedicalscience, 10, 676.
- Marberger (1969). [Value of rectal examination in diseases of the prostatic gland]. Zeitschrift fur Allgemeinmedizin, 45(26), 1210-3.
Review
- Tripathi N, Fortuna GG, Gebrael G, Dal E, Mathew Thomas V, Gupta S, Swami (2024). Predictors of response to neoadjuvant therapy in urothelial cancer. Critical reviews in oncology/hematology, 194, 104236.
- Mahlow J, Gupta (2024). Pathology focused review of morphologic subtypes and molecular variants of urothelial carcinoma with an emphasis on clinical/treatment relevance. Urologic oncology,
- Johnson ED, Butler K, Gupta (2021). Bone Health in Patients With Prostate Cancer: An Evidence-Based Algorithm. Federal practitioner, 38(Suppl 3), S20-S26.
Editorial
- Butterfield A, Gupta (2017). Next-generation sequencing in non-muscle-invasive bladder cancer-a step towards personalized medicine for a superficial bladder tumor. Translational andrology and urology, 6(6), 1198-1202.
Letter
- Galarza Fortuna GM, Swami U, Gupta (2025). Response to: Comment on "Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT)". Journal for immunotherapy of cancer, 13(5),
Abstract
- Manish Kohli; Jodie Wong; Yijun Tian; Amir Bitaraf; Claire Hanson; Matt Larsen; Jennifer Lloyd; Julia Batten; Neeraj Agarwal; Umang Swami; Benjamin Maughan; Sumati Gupta; Jonathan Twar (2023). Abstract 6023: Plasma methylome landscape across the spectrum of prostate cancer progression, and differentially methylated region (DMR) based biomarkers of hormonal therapy failure in metastatic hormone-sensitive prostate cancer. 83(7_Supplement), 6023.
- Umang Swami, Caitlin Faust, Samuel Leonhart, Benjamin Haaland, Kristen Jones, Haoran Li, Kamal Kant Kant Sahu, Vinay Mathew Thomas, Tenzin Kunsang Phunrab, Julia Batten, Lindsay Maxwell, Jennifer Lloyd, Manish Kohli, Sumati Gupta, Kelli Thorne, Benjamin L. Maughan, Neeraj Agarwal Huntsman Cancer Institute at the University of Utah, Salt Lake City, U (2023). ENCORE: A phase 2 trial of enfortumab vedotin (EV) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). . 41(6_suppl), TPS294.
- Kamal Kant Kant Sahu, Nishita Tripathi, Beverly Chigarira, Nicolas Sayegh, Vinay Mathew Thomas, Haoran Li, Yeonjung Jo, Georges Gebrael, Puja Iyer, Roberto Nussenzveig, Neeraj Agarwal, Benjamin L. Maughan, Sumati Gupta, Umang Swami Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Hunstman Cancer Institute at the University of Utah, Salt Lake City, UT; University of Utah, Salt Lake City, U (2023). Characterization of the tumor transcriptomic differences by smoking history in locally advanced or metastatic urothelial carcinoma (UC). . 41(6_suppl), 561.
- Jonathan David Tward, Skyler B Johnson, Kristine E. Kokeny, Shane Lloyd, Donald Maurice Cannon, Christopher B. Dechet, Brock ONeil, Robert Stephenson, Kenneth M. Boucher, Sumati Gupta, Umang Swami, Benjamin L. Maughan, Neeraj Agarwal Hunstman Cancer Institute at the University of Utah, Salt Lake City, UT; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; University of Utah, Salt Lake City, UT; Huntsman Cancer Hospital, Salt Lake City, U (2023). Initial results of a phase 2 pilot study of radium-223 and radiotherapy in untreated hormone-naïve men with oligometastatic prostate cancer to bone. 41(6_suppl), 156.
- Kamal Kant Kant Sahu, Haoran Li, Vinay Mathew Thomas, Mallory Benson, Josiah Hawaks, Julian Brown, Kelli Thorne, Kathy Sherwin, Jackson Cheney, Kenneth M. Boucher, Sumati Gupta, Manish Kohli, Umang Swami, Neeraj Agarwal, Benjamin L. Maughan Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; University of Utah, Salt Lake City, UT; Hunstman Cancer Institute at the University of Utah, Salt Lake City, UT; Salt Lake City, U (2023). A phase II study of rucaparib monotherapy in nonmetastatic, hormone-sensitive prostate cancer (nmHSPC) with “BCRAness” genotype (ROAR). 41(6_suppl), 364.
- Petros Grivas, Damien Pouessel, Chandler H. Park, Philippe Barthelemy, Manojkumar Bupathi, Daniel P. Petrylak, Neeraj Agarwal, Sumati Gupta, Aude Flechon, Chethan Ramamurthy, Nancy B. Davis, Alejandro Recio-Boiles, Cora N. Sternberg, Astha Bhatia, Cabilia Pichardo, Mitch Sierecki, Julia Tonelli, Huafeng Zhou, Scott T. Tagawa, Yohann Lorio (2023). Primary analysis of TROPHY-U-01 cohort 3, a phase 2 study of sacituzumab govitecan (SG) in combination with pembrolizumab (Pembro) in patients (pts) with metastatic urothelial cancer (mUC) that progressed after platinum (PT)-based therapy. . 41(6_suppl), 518.
- Wendy Kohlmann, David Nix, Aaron Atkinson, Kenneth M Boucher, Jill Kolesar, Eric A. Singer, Stephen B. Edge, Branda Quintana, Michelle L. Churchman, Bingjian Feng, Laura Graham, John D. Carpten, Alejandro Sanchez, Yousef Zakharia, Lindsey Byrne, Rohit K. Jain, Kenneth G. Nepple, Ahmad Shabsigh, Jad Chahoud, and Sumati Gupt (2022). Inherited germline variants in urothelial cancer: A multicenter whole-exome sequencing analysis.
- S. Gupta , A. Hong , N.N. El-Chaar , C. Young , K. Ramaswamy , B. Xie , S. Bunner , B. Diessner , U. Swam (2022). Real-world first-line (1L) treatment patterns in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC).
- Sumati Gupta, Benjamin Maughan, Manish Kohli, Bradley Cairns, Umang Swami, Neeraj Agarwa (2022). A phase I trial of tremelimumab, durvalumab (MEDI4736) and belinostat in ARID1A mutated cancers with focus on urothelial carcinoma (RESOLVE) .
- Nishita Tripathi; Yeonjung Jo; Nicolas Sayegh; Beverly Chigarira; Blake Nordblad; Vinay Mathew Thomas; Benjamin Haaland; Roberto Nussenzveig; Sumati Gupta; Neeraj Agarwal; Umang Swami; Benjamin L. Maugha (2022). Abstract 5955: Tumor genomic landscape in patients (pts) with and without liver metastasis in metastatic urothelial carcinoma (mUC). . 82(12_Supplement), 5995.
- Sheetal Hardikar; Christopher R. Weil; Shane Lloyd; Jessica N. Cohan; Mark A. Supiano; Jennifer Ose; Anita R. Peoples; Sumati V. Gupta; Kaitlyn Pelletier; Martine Extermann; Erin M. Siegel; David Shibata; Cornelia M. Ulric (2022). Abstract 36: Treatment patterns in stage I-III colorectal cancer patients over 65 years of age. 82(12_Supplement), 36.
- Shilpa Gupta, Ewan Gibb, Guru P. Sonpavde, Sumati Gupta, Benjamin L. Maughan, Neeraj Agarwal, Bradley Alexander McGregor, Christopher Weight, Xiao X. Wei, David Johnson Einstein, Christopher B. Dechet, Mark A. Preston, Matthew Mossanen, Bharat Thygarajan, Markus Eckstein, C. Marcela Diaz-Montero, Paari J. Murugan, Peter C. Black, Badrinath R. Konet (2022). Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy. . 40(6_suppl), 528.
- Samantha Greenberg, Elizabeth Orlando, Morgan Devlin, Sara Low, Amanda Anson, Brock O Neil, Wendy Kohlmann, Bob Wong, Christopher B. Dechet, Alejandro Sanchez, Jonathan David Tward, Skyler B Johnson, Neeraj Agarwal, Manish Kohli, Sumati Gupta, Umang Swami, Benjamin L. Maughan; Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Huntsman Cancer Institute, Salt Lake City, UT; University of Utah, Salt Lake City, U (2022). Comparing pretest video genetic education for prostate cancer patients: Do patients need assistance? . 40(16_suppl), 5061.
- Neal Shiv Chawla, Nishita Tripathi, Nicolas Sayegh, Ameish Govindarajan, Nazli Dizman, Zeynep Busra Zengin, Luis A Meza, Ramya Muddasani, Alex Chehrazi-Raffle, Sabrina Salgia, Jasnoor Malhotra, Joann Hsu, Errol James Philip, Cristiane Decat Bergerot, Yung Lyou, Umang Swami, Sumati Gupta, Benjamin L. Maughan, Neeraj Agarwal, Sumanta K. Pa (2022). Association between TERT promoter mutations and clinical outcome with immune checkpoint inhibitor therapy for advanced urothelial cancer. 40(6_suppl), 561.
- Yung Lyou, Petros Grivas, Jonathan E. Rosenberg, Jean H. Hoffman-Censits, David I. Quinn, Daniel Peter Petrylak, Matt D. Galsky, Ulka N. Vaishampayan, Ugo De Giorgi, Sumati Gupta, Howard A. Burris III, Jessica Rearden, Corina Andresen, Hao Wang, Siamak Daneshmand, Dean F. Bajorin, and Sumanta K. Pa (2020). Infigratinib and treatment response in advanced/unresectable or metastatic urothelial carcinoma in first-line and later-line treatment settings. . 38(15_suppl), 5038-5038.
- Praful Ravi, Gregory Russell Pond, Leonidas Nikolaos Diamantopoulos, Rohit K. Jain, William Paul Skelton, Sumati Gupta, Jonathan David Tward, Kathleen Olson, Parminder Singh, Camilla Marisa Grunewald, Guenter Niegisch, Jae-Lyun Lee, Andrea Gallina, Marco Bandini, Andrea Necchi, Matthew Mossanen, Bradley Alexander McGregor, Catherine Curran, Petros Grivas, and Guru Sonpavd (2020). Dissecting outcomes of patients (pts) with <ypT2N0 disease after neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC): Results from a large, international, multicenter collaboration. . 38(15_suppl), 5043-5043.
- Lesli Ann Kiedrowski, Roby Antony Thomas, Nicholas J. Vogelzang, Guru Sonpavde, Sumati Gupta, Theodore Stewart Gourdin, Bishoy Morris Faltas, Rebecca Nagy, Richard B. Lanman, and Petros Griva (2020). FGFR2/3 genomic alterations (GA) in cell-free (cf)DNA from patients (pts) with advanced urothelial carcinoma (aUC). . 38(6_suppl), 565-565.
- Yung Lyou, Petros Grivas, Jonathan E. Rosenberg, Jean H. Hoffman-Censits, David I. Quinn, Daniel Peter Petrylak, Matt D. Galsky, Ulka N. Vaishampayan, Ugo De Giorgi, Sumati Gupta, Howard A. Burris, Jessica Rearden, Yining Ye, Hao Wang, Susan Moran, Siamak Daneshmand, Dean F. Bajorin, and Sumanta K. Pa (2020). Relationship between hyperphosphatemia with infigratinib (BGJ398) and efficacy in FGFR3-altered advanced/metastatic urothelial carcinoma (aUC). . 38(6_suppl), 576-576.
- Shilpa Gupta, Guru Sonpavde, Christopher J. Weight, Bradley Alexander McGregor, Sumati Gupta, Benjamin Louis Maughan, Xiao X. Wei, Ewan Gibb, Bharat Thyagarajan, David Johnson Einstein, Christopher B. Dechet, William Thomas Lowrance, Paari J Murugan, Kerry L. Kilbridge, Neeraj Agarwal, Elai Davicioni, Markus Eckstein, Matthew Mossanen, Mark A. Preston, and Badrinath R. Konet (2020). Pl Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. 38(6_suppl), 439-439.
- Petros Grivas, Yohann Loriot, Susan Feyerabend, Rafael Morales-Barrera, Min Yuen Teo, Nicholas J. Vogelzang, Enrique Grande, Yousef Zakharia, Nabil Adra, Ajjai Shivaram Alva, Andrea Necchi, Sumati Gupta, Debra Hannah Josephs, Alejo Rodriguez-Vida, Sandy Srinivas, Kenton Wride, Daleen Thomas, Rachel Dusek, Dale L. Nepert, and Simon Chowdhur (2020). Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): Results from ATLAS, a phase II open-label trial. . 38(6_suppl), 440-440.
- Sumati Gupta, Benjamin Louis Maughan, Christopher B. Dechet, William Thomas Lowrance, Brock O Neil, Kristine E. Kokeny, Shane Lloyd, Jonathan David Tward, Kenneth M. Boucher, and Neeraj Agarwa (2020). NEXT: A phase II, open-label study of nivolumab adjuvant to chemoradiation in patients (pts) with localized muscle invasive bladder cancer. 38(6_suppl), TPS605-TPS605.
- Benjamin Louis Maughan, Andrew W Hahn, Roberto Nussenzveig, John Hoffman, Kathryn Morton, Sumati Gupta, Julia Anne Batten, Jared Thorley, Josiah Hawks, Victor Sacristan Santos, Gayatri Nachaegari, Xuechen Wang, Kenneth M. Boucher, Benjamin Haaland, and Neeraj Agarwa (2020). Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Long-term follow up of secondary endpoints. 38(6_suppl), 125-125.
- Benjamin Louis Maughan, Alejandro Sanchez, Brock B. O'Neil, William Thomas Lowrance,Christopher B. Dechet, Danel Joseph Albertson, Deepika Sirohi, Sumati Gupta, Umang Swami, and Neeraj Agarwa (2020). A phase 1b/II trial of perioperative intratumoral MVA-BN-brachyury (MVA) plus systemic PROSTVAC and atezolizumab (Atezo) for intermediate-risk and high-risk localized prostate cancer (AteoVax). 38(6_suppl), TPS382-TPS382.
- Benjamin Louis Maughan, Roberto Nussenzveig, Umang Swami, Sumati Gupta, and Neeraj Agarwa (2020). Prospective trial of nivolumab (Nivo) plus radium-223 (RA) in metastatic castration-resistant prostate cancer (mCRPC) evaluating circulating tumor DNA (ctDNA) levels as a biomarker of response. 38(6_suppl), TPS267-TPS267.
- Sergiusz Wesolowski Roberto Nussenzveig, Victor Sacristan Santos, John Esther, Divyam Goel, Umang Swami, Sumati Gupta, Benjamin Louis Maughan, Mark Yandell, Petros Grivas, and Neeraj Agarwa (2020). Genomic correlates of response to PD-1 axis inhibitors (IO) in metastatic urothelial cancer (mUC) using explainable artificial intelligence (AI). 38(6_suppl), 570-570.
- A Necchi,D Pouessel, R Leibowitz-Amit, A Flechon, S Gupta, P Barthelemy, M Maio, X Zhu, E Asatiani, G Serbest, H Zhen, Y Lorio (2018). Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA).
- Gupta, (2018). ATLAS: A phase II, open-label study of rucaparib in patients (pts) with locally advanced (unresectable) or metastatic urothelial carcinoma.
- Petros Grivas, Gregory Russell Pond, Rebecca J Nagy, Pedro C. Barata, Prateek Mendiratta, Dharmesh Gopalakrishnan, Alexandra Drakaki, Sumati Gupta, Neeraj Agarwal, Jue Wang, Bishoy Faltas, Ulka N. Vaishampayan, Gurudatta Naik, Bradley Alexander McGregor, Sumanta K. Pal, Lesli Ann Kiedrowski, Richard B. Lanman, Guru Sonpavd (2018). Association of circulating tumor (ct)-DNA genomic alterations (GA) with outcomes in metastatic urothelial carcinoma (mUC). ASCO Annual Meeting 2018.
- Jacob Adashek, Sumanta K. Pal, Vincent M. Chung, Scott T. Tagawa, Joel Picus, Hani M. Babiker, Sumati Gupta, Raymond Couric Wadlow, Julie Poore, Christine Peterson, Ely Benai (2018). Preliminary results from an ongoing phase 2a study of RX-3117, an oral nucleoside analogue to treat advanced urothelial cancer (aUC). ASCO Annual Meeting 2018.
- Sumati Gupta, Andrew Butterfield, Timothy Parnell, Alexis Weston, Mohan Kaadige, Sunil Sharm (2018). Reversible LSD1 (KDM1A) inhibition with HCI2509 is growth inhibitory in bladder cancer cell lines and causes gene expression changes that reveal rational therapeutic partners.
- Grivas P, Nagy RJ, Pond GR, Gupta S, Wang J, Vaishampayan UN, Pal SK, Bilen MA, Naik G, Ghatalia P, Hoimes CJ, Gopalakrishnan D, Barata P, Lanman RB, Talasaz AA, Sonpavde (2017). Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape.
- Poole A, Gill DM, Hahn AW, Johnson E, Carroll E, Batten JA, Gupta S, Boucher KM, Maughan BL, Agarwal (2017). Incidence and characterization of antiandrogen withdrawal syndrome (AAWS) after enzalutamide (ENZA) in patients (pts) with metastatic castration-refractory prostate cancer (mCRPC).
- Carroll E, Gill DM, Poole A, Hahn AW, Bailey EB, Streeter J, Batten JA, Gupta S, Agarwal N, Maughan B (2017). Genomic diversity between primary tumor tissue and tumor circulating cell-free DNA (cfDNA) in patients (pts) with metastatic prostate cancer.
- Gill DM, Stenehjem DD, Cheng HH, Kessler ER, Hahn, AW, Gupta S, Alex A, Patel SB, Chittoria N, Twardowski P, Vaishampayan UN, Agarwal N (2017). Association of time from definitive therapy (DT) to start of androgen deprivation therapy (ADT) for metastatic disease and survival outcomes in men with new metastatic hormone-sensitive prostate cancer (mHSPC).
- Pandha HS, Ralph C, Harrington K, Curti BD, Sanborn RE, Akerley WL, Gupta S, Rudin CM, Rosenberg JE, Kaufman DR, Schmidt EV, Grose M, Shafren (2017). Keynote-200 phase 1b: A novel combination study of intravenously delivered coxsackievirus A21 and pembrolizumab in advanced cancer patients.
- Gong J, Chung VM, Picus J, Tagawa ST, Gupta S, Poore J, Peterson C, Benaim E, Pal S (2017). Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with metastatic bladder cancer resistant to gemcitabine: Preliminary results of a phase Ia/IIb study.
- Choueiri TK, Larkin JMG, Oya M, Thistlethwaite FC, Martignoni M, Nathan PD, Powles T, McDermott DF, Robbins PB, Chism DD, Cho DC, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, di Pietro A, Rini B (2017). First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.
- Grivas P, Nagy RJ, Pond GR, Gupta S, Wang J, Vaishampayan UN, Pal SK, Bilen MA, Naik G, Ghatalia P, Gopalakrishnan D, Barata P, Lanman RB, Talasaz AA, Sonpavde (2017). Circulating tumor (ct)-DNA alterations in advanced urothelial carcinoma: Association with outcomes and evolution with therapy.
- Gupta S, Albertson DJ, Parnell T, Dalley B, O Shea J, Weston A, Butterfield A, Pappas LM, Schiffman JD, Sharma S, Agarwal (2017). Clinical and translational investigation of pan-HDAC inhibition in advanced urothelial carcinoma (UC).
- Gupta S, Albertson DJ, Gaston D, Heilbrun ME, Agarwal N, Liu T, Miller VA, Ross JS, Milis SZ, Ali S (2017). Comprehensive genomic sequencing of urothelial tumors to identify rare driver genomic alterations in SMARCB1 in a subset of patients.
- Hahn AW, Gill DM, Streeter J, Bailey EB, Carroll E, Aryal L, Batten JA, Gupta S, Agarwal N, Maughan B (2017). Intra-individual genomic diversity between circulating tumor cell-free DNA (cfDNA) and tumor tissue testing in metastatic renal cell carcinoma (mRCC).
- Ahmad Halwani, Zachary Burningham, Kelli M Rasmussen, Vikas Patil, Sujata Narayanan, Shih-Wen Lin, Susheela Carroll, Ling-I Hsu, Julie Graff, Robert Dreicer, Sumati Gupta, Clarke Low, Brian C Saue (2017). Practice Patterns in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Evidence From the Veterans Health Administration.
- Kelli M Rasmussen, Vikas Patil, Zachary Burningham, Sujata Narayanan, Shih-Wen Lin, Susheela Carroll, Ling-I Hsu, Julie Graff, Robert Dreicer, Sumati Gupta, Clarke Low, Brian C Sauer, Ahmad Halwan (2017). The role of academic affiliation in the treatment of metastatic castrate-resistant prostate cancer in the Veterans Health Administration Abstract- AVAHO 2017.
- Ahmad Halwani, Kelli M. Rasmussen, Vikas Patil, Zachary Burningham, Sujata Narayanan, Shih-Wen Lin, Susheela Carroll, Ling-I Hsu, Julie N. Graff, Robert Dreicer, Sumati Gupta, Clarke Low, Brian C, Saie (2017). Racial Disparities in Metastatic Castrate-Resistant Prostate Cancer (mCRPC): Evidence from the Veteran's Health Administration (VHA) AACR.
- Sumanta Pal, Vincent Chun, Scott Tagawa, Joel Picus, Sumati Gupta, Julie Poore, Christine Peterson and Ely Benai (2017). RX-3117, an Oral Hypomethylating Agent to Treat Advanced Solid Tumors (ST): Interim results from an Ongoing Phase 2a Study in Metastatic Bladder Cancer.
- Nagy RJ, Agarwal N, Gupta S, Pal SK, Grivas P, Vaishampayan UN, Wang J, Naik G, Lanman RB, Talasaz AA, Sonpavde G (2016). Circulating cell-free DNA profiling of patients with advanced urotheial carcinoma of the bladderÏ.
- Agarwal N, Heemers H, Farnham JM, Patel SB, Gill D, Gupta S, Teerlink C, Stephenson RA, Alex A, Cannon-Albright L (2016). Association of single nucleotide polymorphisms (SNPs) in TPD52 gene with response to treatment with enzalutamide (ENZA) in men with metastatic castration refractory prostate cancer (mCRPC).
- Gupta (2016). A Phase 2 Study of the Histone Deacetylase (HDAC) Inhibitor Mocetinostat in Patients with Urothelial Carcinoma (UC) and Inactivating Alterations of Acetyltransferase Genes.
- Stenehjem D, Gupta S, Wade M, Gilcrease G, Garrido-Laguna I, Weis JR, Whisenant J, Sharma (2016). A phase I dose escalation trial to assess the safety and preliminary efficacy of mFOLFOX6 combined with pembrolizumab (MK3475) in advanced gastrointestinal malignancies. 2016,
- Gupta S, Weston A, Bearrs J, Soldi R, Sharma (2015). Effect of LSD-1 inhibition on docetaxel resistance in prostate cancer cells.
- Gupta (2002). Retrospective study on the effect of chronic ACE inhibitor therapy on inter-dialysis weight gain in patients on hemodialysis. Renal failure, Jul;24(4), 461-6.
Other
- Hillary Finch, Clark Low, Sumati Gupt (2018). FGFR pathways and their role in oncologic therapy: Focus on Phase I Newsletter.
- Nikita Pandya, Robert Hanlon, Andrew Butterfield,Sumati Gupt (2017). Epigenetics in Cancer: A Review.
- Kharkar VJ, Ast A, Gupta S, Sharma (2016). LSD2/KDM1B/AOF1 and Human Cancer Pathways: A Literature Review. 1(1), 1-5.
- Gupta (2015). Epigenetics in Bladder Cancer.
Dr G is a compassionate professional...A+++
She is just excellent to have for a doctor
THE BEST ON THE PLANET
Dr. Gupta is a very good Dr. she is always ready to give the best help.
The Best. a 10 plus
Dr G has earned my respect and trust
She's great ! Tenzen is Great too
The team is very easy to deal with and explaining the procedures and time frame.
It only takes 2 words. ¿The Best¿.
Dr Gupta is very nice and she cares about may health
Excellent in explaining and knowledge
Wonderful oncologist and really knows her stuff.......as good as it gets! I trust her with my life!
Even though I did not see her this visit, her staff is wonderful
Very knowledgeable and concerned about your quality of life!!
I was left somewhat puzzled by her instructions considering the most recent testing I had.
I am so fortunate to have Dr. Gupta as one of my trusted Physicians, she is amazing !
She is very knowledgeable,and professional!
Very caring Doctor!!
Good
She make decisions, and explains why.
She is the most wonderful person, and makes me feel good
she is very nice
Dr Gupta explains everything so clearly and does not rush you.
She is just wonderful. We couldn't ask for a better cancer doctor
Thorough
Dr. Gupta is very compassionate and knowledgeable
Up beat and professional, I trust her with my life!
Bright, interested in me as her patient, explained everything extremely well about my treatment and what steps would be taken in sequence if my conditioned worsened, answered questions clearly and prompted or suggested additional questions, wrote down what she was telling me for me to keep. I was very impressed.
Dr. Gupta is fantastic. Very thorough. No rock left unturned.
She is confident and very respectful
She is very nice and pays attention to all my needs
she is one of the many WONDERFUL doctors at this location
When you leave Dr Gupta, you leave feeling like a person and not a patient. She makes me feel like I really matter. And I leave understanding the treatments available to me
Dr. Gupta is a uniquely committed person. She truly cares about her patients.
Dr. Gupta explained everything completely to me and was very attentive to my response to her questions
she is very nice
The Best.
dr. Gupta is a very good Dr. she tried me very well.
very thorough and genuine in her concern for me and ensuring i get the proper treatment. Setting me up with everything i need to be successful in response to the prescribed treatment.
Always positive and help me feel reassured.
Excellent about explaining my treatment
she is very nice and a good doctor. She knows what she is doing
Dr. Gupta's care brought me back from the brink.
I have complete confidence in doc and her staff
Dr. Gupta is everything you want and need your oncologist to be. Attentive, knowledgeable, calm, willing to network a lot with other physicians weighing the pros and cons of aspects of your care behind the scenes, etc.
Dr Gupta is great at making sure the care I am getting is the best. I value her opinion and care.
We have great confidence in Dr Gupta's plan for cancer treatment. She is very knowledgeable in her field,
Dr. Gupta was very informative and clearly explained what was needed to take care of my issues.
Very good doctor
Has been very keeping me informed
A brilliant doctor who takes time with her patients. She wants the patient to clearly understand situations and options. We are lucky to be under her care,
Dr. Gupta is everything you want in your oncologist: thorough, attentive, actually listens to her pts, goes out of her way to see you when unexpected symptoms come up, is sensitive to life quality vs quantity balance, and manages her care team well.
I appreciate their professional advice, help, and kindness. Everyone on Dr. Gupta's team is amazing and made me feel comfortable, confident, and loved. I would recommend her team to anyone. Special shoutout to Kendra, Dr. Gupta's nurse.
Dr Gupta is a 10 plus. Her knowledge, experience and compassion is beyond words.
Dr Gupta, and her team are caring, friendly and very knowledgeable in their care, she saved my life.
Dr G and staff know their stuff. Consistently impressive! I trust them completely.
Very helpful explaining everything. Felt like she really cared about me. I also felt like she would go to battle for me. Very kind and caring! Really like her.
Extremely knowledgeable, helpful and considerate
What a very good doctor she is. She's very thorough. I'm very happy to have her as my medical doctor.
Dr Gupta's staff is excellent.......she runs a tight ship!!!!
She always makes sure that my questions are answered
I appreciate Dr. Gupta's knowledge and professionalism. She cares about me as a patient, and I feel confident in her care. She explains things well, and her staff is also top-notch, easy to communicate with, and quick to answer any additional questions I may have. I feel blessed this team is treating me.
Very helpful in explaining everything and answering questions.
Es mi buena doctora te hace sentir bien y te escucha tus problemas
La Dra. Gupta es una profesional de primer nivel, Gracias a ella y su experiencia, profesionalismo y preocupación con sus pacientes, pude superar y sanar mi enfermedad aún sigo en control. Mi familia y yo estamos eternamente agradecidos a su atención y preocupación por mi caso. Dios la bendiga y siga apoyando en sus servicios que tanto se necesitan. Muchas Gracias
It was very meaningful and informative visit. I was so impressed with her and he staff, who were so caring and respectful. It was so pleased with the Dr. approach to my specific situation, obtaining important information and then explaining a variety of options that coulc be applicable in the future as we progress toward a treatment plan. I have total confidence in her ability to do what is best for me now and in the future. She is credit to the institution. Take good care of her!
A Ella no la veo la persona que me atiende es su ayudante
Dr. Gupta is very considerate of my concerns. She is very kind and works hard explain things in a way that I can understand them.
My Team is the best. 10+
Dr. Gupta treats me like a family member not just as any patient off the street.
Dr Gupta, APRN Tenzin Phunrab and her team are caring, friendly and knowledgeable in their care.
I did not meet with Dr. Gupta this appointment so I am answering from past experience. Her staff is excellent.
It is a work in progress. I believe Dr. Gupta will solve my problem.
She made sure I understood what she was saying. And wanted to know if I agreed
I appreciate her taking the time to explain and suggest treatment options. She was very easy and clear to understand.
Very patient and caring
She is very thorough and yet very empathy towards my feelings and making sure I understand where we are going with my treatment
Dr Gupta, is excellent!!!
Dr. Gupta shows concern for patients and is very personable in her communications with them.
She explained very well
Dear Dr. Gupta, Thank you and your staff so much for all of your help this year!!!
She does not shy away from painful discussions. This is a great help in managing my personal matters. She is also willing to communicate with my physician daughter. This is a great help to my family who does not need to listen to y "engineering" interpretations of medical facts..
She is a very good doctor
Dr. Gupta is caring and thorough in her analysis of my health.
I trust Dr. Gupta totally to take care of my medical needs.
Dr Gupta is great!
This doctor is truly amazing. I honestly wish she was at a different facility.
Answered all our questions an explained medical terms in a way that was easily understood.
They are always very good!
Good
Great
Very good
10 plus
Very good
Thought I had decent info before arriving after out visit it was so much more I formed and shared in a caring manner felt confident and comfortable with the doctors abilities to explain to my understanding cared about my concerns and questions.
Excellent
Everybody was super informative and helpful !!
Excellent yeam
This was one of the best experiences I've had.
Dr Gupta is the best
I am glad to be in your care
Dr Gupta was very considerate and kind with the questions I asked.
We are so pleased with the treatment here that we have recommended several friends/individuals we know who are undergoing treatment for cancer to come for an evaluation and possibly transfer their care to this facility.
Total care from reception to nurse to doctor concern and care was above exceptional.
I feel they really care.
Very good
Dr Gupta is very professional and compassionate. She is very open an will discuss all options
Dr Gupta is very professional an compassionate. I respect her imensily
Excellent
Detailed and realistic and well explained.
Dr Gupta is very patient an listens to all my questions an input
very good
Dr Gupta and her team are very compassionate and caring. I know Dr Gupta is very busy, but she will stay an address all of my questions and concerns.
all appointments were right on time.
always takes time to ask questions an show concern
lots of information. was good about listening and answering wuestions
Dr Gupta was kind enough to answer my questions that I had. Very patient and kind
Dr Gupta, Tenzin, and Courtney spent about a hour with me. Addressed all my questions, and were very professional
explain more about procedures and other choices
I have few things that I can do
Dr Gupta takes time to have discussion about my current situation. addressing all my concerns
Care was, as always, a 10 plus.
Dr Gupta spent time explaining current situation and answered all my questions
good
dr Gupta was excellent
Dr. Gupta is the best
Dr Gupta spent the time to discuss my situation.
Dr draw a pictorial about meditation advancements.
no sugar coating! lets deal with what we know, and here is our plan of attack. all said in a caring manner. made us feel like "we got this!"
I don't feel qualified to tell people who should give them medical care
none
I hoped I would receive more information about my. condition after my provider consulted with the expert at Huntsmans to read my CT scan, and that I would receive by USMail the results of my tests, as my provider promised.